Literature DB >> 18593021

GIST as the model of paradigm shift towards targeted therapy of solid tumors: update and perspective on trial design.

Jaap Verweij1, Caroline Seynaeve, Stefan Sleijfer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18593021     DOI： 10.1007/978-0-387-73898-7_11

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  2 in total

1.  Tuberculous and non-tuberculous granulomatous lymphadenitis in patients receiving imatinib mesylate (glivec) for metastatic gastrointestinal stromal tumor.

Authors:  Abbas Agaimy; Valeska Brueckl; Daniela Schmidt; Stephanie Krieg; Evelyn Ullrich; Norbert Meidenbauer
Journal:  Case Rep Oncol       Date:  2013-03-05

2.  A systems approach defining constraints of the genome architecture on lineage selection and evolvability during somatic cancer evolution.

Authors:  Albert Rübben; Ole Nordhoff
Journal:  Biol Open       Date:  2012-11-02       Impact factor: 2.422
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.